US Patent

US7834059 — Topical nepafenac formulations

Method of Use · Assigned to Alcon Inc · Expires 2027-01-31 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects topical nepafenac formulations, especially suitable for topical ophthalmic administration.

USPTO Abstract

Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.

Drugs covered by this patent

Nevanac (NEPAFENAC) · Harrow Health

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1095`	—	Nevanac

Patent Metadata

Patent number: US7834059
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-31
Drug substance claim: No
Drug product claim: No
Assignee: Alcon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.